Last updated: February 23, 2026
What Is NDC 83390-0107 and Its Therapeutic Profile?
NDC 83390-0107 is identified as Rytary (carbidopa and levodopa extended-release capsules). Rytary is indicated for symptomatic management of Parkinson’s disease and has been on the market since 2015.
Market Overview
The Parkinson’s disease (PD) treatment market is expanding due to increasing diagnosis rates globally. The market was valued at approximately $4.15 billion in 2021 and is expected to grow at a CAGR of 4.5% through 2028. Rytary holds a significant share within the PD medications segment.
Key Market Drivers
- Rising PD prevalence: Estimated at 1 million in the US.
- Advancements in drug formulations: Extended-release medications like Rytary improve patient compliance.
- Competition from generic levodopa products: These exert downward pressure on branded prices.
Major Competitors
| Drug Name |
Market Share (2022) |
Price Range (per unit) |
Formulation Type |
| Rytary |
45% |
$16 - $25 |
Extended-release capsules |
| Sinemet (generic) |
25% |
$5 - $8 |
Immediate-release tablets |
| Duopa |
15% |
$17 - $23 |
Enteral suspension |
| Others |
15% |
N/A |
Various |
Past and Present Pricing Trends
Rytary Pricing History
| Year |
Average Wholesale Price (AWP) |
Estimated Retail Price |
Notes |
| 2015 |
$17.00 |
$20 - $25 |
Launch period |
| 2018 |
$16.50 |
$19 - $24 |
Slight decline due to market competition |
| 2022 |
$15.50 |
$18 - $22 |
Stabilization, generic competition rising |
Prices have generally declined over the past five years, driven mainly by increased generic competition and formulary adjustments.
Price Projection Outlook
Near-Term (1-2 Years)
Expect prices to stabilize around $15-$18 per unit in the retail segment, with possible minor declines due to:
- Increased availability of generic formulations.
- Payor negotiations favoring lower-cost options.
Mid to Long-Term (3-5 Years)
Potential price adjustments could lead to further declines of 10-15%, assuming increased generic market penetration. Innovation in delivery systems or combination formulations could offset price erosion temporarily.
Influencing Factors
- Regulatory policy shifts promoting biosimilar or generic drug uptake.
- Patent expirations or legal challenges impacting exclusivity.
- Changes in reimbursement and formulary arrangements.
Revenue and Market Share Projections
Projected sales for Rytary are expected to decline slightly as generics capture market share. Based on current data:
| Year |
Estimated Sales (USD Billions) |
Market Share |
Comments |
| 2022 |
$500 million |
45% |
Leading branded product |
| 2025 |
$400 million |
30-35% |
Increased generic availability |
| 2030 |
$300 million |
20-25% |
Dominance of generics over branded |
Regulatory and Patent Considerations
The original patent for Rytary expired in 2020, with some secondary patents extending protection until 2023-2024. Recent challenges and patent litigations are contributing to price pressure and market erosion.
Key Takeaways
- Rytary remains a significant player in the Parkinson’s disease treatment segment, but market share is declining.
- Prices are trending downward, with retail prices averaging $15-$18 per unit by 2023.
- Competitive pressures from generics will intensify, likely reducing prices further by 2025.
- Revenue projections indicate a gradual decline, emphasizing the importance of innovation and lifecycle management.
FAQs
1. How does Rytary compare to other PD drugs in terms of price?
Rytary’s retail price is higher than immediate-release formulations like generic Sinemet, which can be priced below $8 per unit. Extended-release formulations generally cost more due to convenience and improved symptom management.
2. What factors impact Rytary's market share?
Patent expiration, generic drug entry, payor preferences, and formulary placements influence market share. Market share declines as generics become more accessible and accepted.
3. Will Rytary's price decline continue?
Yes, increased generic competition and patent challenges are likely to drive prices downward over the next 2-3 years.
4. Are there new formulations or pipeline drugs expected to impact this market?
Yes, several pipeline drugs aim to improve PD management, which could further influence Rytary's market dynamics through differentiation or substitution.
5. What is the outlook for Rytary's revenues in the next five years?
Revenues are projected to decline from approximately $0.5 billion in 2022 to about $0.3 billion in 2030, assuming no major innovations or market disruptions.
References
[1] International Parkinson and Movement Disorder Society. (2022). Parkinson's disease: Epidemiology. Retrieved from https://www.movementdisorders.org
[2] IQVIA. (2022). U.S. Prescription Audit.
[3] EvaluatePharma. (2022). Market Intelligence Report.
[4] FDA. (2020). Patent litigation and generic drug approvals.
[5] DrugPriceInfo. (2023). Trends in Parkinson's disease medications.
